electroCore, Inc. (ECOR)

NASDAQ: ECOR · Real-Time Price · USD
4.820
+0.170 (3.66%)
At close: May 12, 2025, 4:00 PM
4.820
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
3.66%
Market Cap 34.67M
Revenue (ttm) 26.46M
Net Income (ttm) -12.24M
Shares Out 7.19M
EPS (ttm) -1.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 345,494
Open 4.790
Previous Close 4.650
Day's Range 4.502 - 4.995
52-Week Range 5.020 - 19.490
Beta 0.92
Analysts Strong Buy
Price Target 25.50 (+429.05%)
Earnings Date May 7, 2025

About ECOR

electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electron... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 22, 2018
Employees 73
Stock Exchange NASDAQ
Ticker Symbol ECOR
Full Company Profile

Financial Performance

In 2024, electroCore's revenue was $25.18 million, an increase of 57.09% compared to the previous year's $16.03 million. Losses were -$11.89 million, -36.89% less than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ECOR stock is "Strong Buy." The 12-month stock price forecast is $25.5, which is an increase of 429.05% from the latest price.

Price Target
$25.5
(429.05% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

electroCore, Inc. (ECOR) Q1 2025 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Dan Goldberger - Chief Executive Officer and Director Joshua Lev - Chief Financial Officer...

4 days ago - Seeking Alpha

electroCore Announces First Quarter 2025 Financial Results

First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of ap...

5 days ago - GlobeNewsWire

electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

Addition of Quell® Platform Broadens electroCore's Bioelectronic Technology Portfolio and Accelerates Growth in Chronic Pain and Wellness Markets Addition of Quell® Platform Broadens electroCore's Bio...

10 days ago - GlobeNewsWire

electroCore's Truvaga™ Now Works with the Apple Health app

ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, T...

11 days ago - GlobeNewsWire

electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025

ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the ...

12 days ago - GlobeNewsWire

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025...

25 days ago - GlobeNewsWire

electroCore to Participate at the Planet MicroCap Showcase

ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in...

26 days ago - GlobeNewsWire

electroCore Named One of The Americas' Fastest Growing Companies by the Financial Times

ROCKAWAY, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, has been recognized by the Financial Times as one o...

5 weeks ago - GlobeNewsWire

electroCore to Participate at the Needham Virtual Healthcare Conference

ROCKAWAY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at...

5 weeks ago - GlobeNewsWire

electroCore Extends VA Contract for Five Years

ROCKAWAY, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that electroCore has received a new...

6 weeks ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q4 2024 Results Conference Call March 12, 2025 5:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Par...

2 months ago - Seeking Alpha

electroCore Announces Full Year 2024 Financial Results

Record f ull year 2024 net sales of $ 25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCore TM   in the United States Department of Veteran A...

2 months ago - GlobeNewsWire

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial r...

2 months ago - GlobeNewsWire

electroCore to Participate at Upcoming Investor Conferences

Management to Attend the 37th Annual Roth Conference and the LSI USA '25 Management to Attend the 37th Annual Roth Conference and the LSI USA '25

2 months ago - GlobeNewsWire

electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal

ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent™ by Spark Biomed...

2 months ago - GlobeNewsWire

electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

ROCKAWAY, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its participation in the 12th Annual...

3 months ago - GlobeNewsWire

electroCore: An Opportunity In Medical And Wellness Device Innovation

electroCore, Inc. (ECOR) shows promising growth with a 45% YoY revenue increase and a 38% loss reduction, despite missing revenue expectations. The company's gammaCore device is FDA-cleared for headac...

4 months ago - Seeking Alpha

electroCore Has Only Just Begun To Scratch The Surface Of Its Huge TAM

electroCore's gammaCore, an FDA-approved nVNS device, generates recurring revenue and has significant expansion potential within the VA system and other healthcare channels. The company is diversifyin...

4 months ago - Seeking Alpha

electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector

5 months ago - GlobeNewsWire

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21

ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in ...

6 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call...

6 months ago - Seeking Alpha

electroCore Announces Third Quarter 2024 Financial Results

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales

6 months ago - GlobeNewsWire

ElectroCore's Truvaga™ Plus Wins Men's Health Magazine Tech Award

ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness prod...

6 months ago - GlobeNewsWire

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freebur...

6 months ago - GlobeNewsWire

electroCore to Participate at LD Micro Main Event VXII

Rockaway, New Jersey--(Newsfile Corp. - October 14, 2024) - electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will parti...

7 months ago - Newsfile Corp